Log in

NASDAQ:MDGLMadrigal Pharmaceuticals Stock Price, Forecast & News

$109.37
-2.21 (-1.98 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$108.94
Now: $109.37
$113.95
50-Day Range
$102.74
MA: $113.33
$125.71
52-Week Range
$56.82
Now: $109.37
$127.25
Volume143,300 shs
Average Volume142,108 shs
Market Capitalization$1.69 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.3
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.
Read More
Madrigal Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.84 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MDGL
CUSIP87162T20
Phone267-824-2827

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$27.00 per share

Profitability

Net Income$-83,950,000.00

Miscellaneous

Employees17
Market Cap$1.69 billion
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive MDGL News and Ratings via Email

Sign-up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter.

Madrigal Pharmaceuticals (NASDAQ:MDGL) Frequently Asked Questions

How has Madrigal Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Madrigal Pharmaceuticals' stock was trading at $81.06 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MDGL shares have increased by 34.9% and is now trading at $109.37. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Madrigal Pharmaceuticals?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Madrigal Pharmaceuticals.

When is Madrigal Pharmaceuticals' next earnings date?

Madrigal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Madrigal Pharmaceuticals.

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) released its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($2.34) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.94) by $0.40. View Madrigal Pharmaceuticals' earnings history.

What price target have analysts set for MDGL?

11 analysts have issued 12 month price targets for Madrigal Pharmaceuticals' stock. Their forecasts range from $116.00 to $205.00. On average, they expect Madrigal Pharmaceuticals' share price to reach $164.22 in the next twelve months. This suggests a possible upside of 50.2% from the stock's current price. View analysts' price targets for Madrigal Pharmaceuticals.

Has Madrigal Pharmaceuticals been receiving favorable news coverage?

Media stories about MDGL stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Madrigal Pharmaceuticals earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Madrigal Pharmaceuticals.

Are investors shorting Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals saw a decline in short interest during the month of June. As of June 15th, there was short interest totaling 2,860,000 shares, a decline of 8.6% from the May 31st total of 3,130,000 shares. Based on an average daily trading volume, of 229,300 shares, the days-to-cover ratio is presently 12.5 days. Approximately 33.1% of the company's stock are short sold. View Madrigal Pharmaceuticals' Current Options Chain.

Who are some of Madrigal Pharmaceuticals' key competitors?

What other stocks do shareholders of Madrigal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Viking Therapeutics (VKTX), Advaxis (ADXS), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Crispr Therapeutics (CRSP), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Consolidated Water (CWCO).

Who are Madrigal Pharmaceuticals' key executives?

Madrigal Pharmaceuticals' management team includes the following people:
  • Dr. Paul A. Friedman, Chairman & CEO (Age 76)
  • Dr. Rebecca A. Taub, Founder, Exec. VP of R&D, Chief Medical Officer and Director (Age 67)
  • Mr. Marc R. Schneebaum, Sr. VP & CFO (Age 65)
  • Mr. Thomas W. Hare, Sr. VP of Clinical Management

What is Madrigal Pharmaceuticals' stock symbol?

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Madrigal Pharmaceuticals' stock price today?

One share of MDGL stock can currently be purchased for approximately $109.37.

How big of a company is Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals has a market capitalization of $1.69 billion. The biopharmaceutical company earns $-83,950,000.00 in net income (profit) each year or ($5.45) on an earnings per share basis. Madrigal Pharmaceuticals employs 17 workers across the globe.

What is Madrigal Pharmaceuticals' official website?

The official website for Madrigal Pharmaceuticals is www.madrigalpharma.com.

How can I contact Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at 267-824-2827 or via email at [email protected]

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.